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Abstract 11 
Background and purpose: Current automated radiotherapy planning solutions do not allow for the intuitive exploration of different 12 
treatment options during protocol calibration. This work introduces an automated planning solution, which aims to address this 13 
problem through incorporating Pareto navigation techniques into the calibration process. 14 
Materials and methods:  For each tumour site a set of planning goals is defined. Utilising Pareto navigation techniques an operator 15 
calibrates the solution through intuitively exploring different treatment options: selecting the optimum balancing of competing 16 
planning goals for the given site. Once calibrated, fully automated plan generation is possible, with specific algorithms 17 
implemented to ensure trade-off balancing of new patients is consistent with that during calibration. Using the proposed 18 
methodology the system was calibrated for prostate and seminal vesicle treatments. The resultant solution was validated through 19 
quantitatively comparing the dose distribution of automatically generated plans (VMATAuto) against the previous clinical plan, for 20 
ten randomly selected patients. 21 
Results: VMATAuto yielded statistically significant improvements in: PTV conformity indices, high dose bladder metrics, mean bowel 22 
dose, and the majority of rectum dose metrics. Of particular note was the reduction in mean rectum dose (median 25.1Gy vs. 27.5 23 
Gy), rectum V24.3Gy (median 41.1% vs. 46.4%), and improvement in the conformity index for the primary PTV (median 0.86 vs. 0.79). 24 
Dosimetric improvements were not at the cost of other dose metrics. 25 
Conclusions: An automated planning methodology with a Pareto navigation based calibration has been developed, which enables 26 
the complex balancing of competing trade-offs to be intuitively incorporated into automated protocols. 27 
1. Introduction 28 
Inverse radiotherapy planning is a time consuming, iterative process where optimal plan quality is not guaranteed [1]. A solution 29 
to this problem is automated planning (AP) where high quality treatment plans are generated fully autonomously [2–11]. AP has 30 
been implemented using a range of methodologies, which can be categorised within the following three broad domains: 31 
knowledge based planning (KBP), sequential ɸ-constraint optimisations ;ɸĐͿ and protocol based automatic iterative optimisations 32 
(PB-AIO).  33 
KBP utilises information from previously treated patients to inform the optimisation of future patients. The most common 34 
methods use machine learning algorithms, trained on databases of historical treatment plans, to predict the achievable dose 35 
distribution [12,13] or dose volume histograms [14,15] for new patients. This information is utilised during the inverse optimisation 36 
process to generate a plan whose dose distribution best matches that predicted.  37 
ɸĐ generates plans according to a list of prioritised clinical goals, which are minimised in strict sequential order under the condition 38 
that lower priority goals must not compromise higher priority goals. Through the appropriate selection and ordering of goals, a 39 
single prioritised list can generate desirably balanced plans for individual patients within a given treatment site [2,8].  40 
Finally, PB-AIO techniques load an initial set of objectives (either hard coded or derived from a site specific template) into the 41 
plaŶŶiŶg sǇsteŵ͛s native optimiser. During the optimisation process, automated algorithms iteratively adjust objectives based on 42 
information from the optimised dose distribution to tailor the plan to the desired clinical aims [4,16,17]. Specific examples include: 43 
regularly updating objective positions such that a constant distance below the corresponding DVH line is maintained [18] and 44 
ŵodulatiŶg oďjeĐtiǀe ǁeights suĐh that the fuŶĐtioŶ͛s oďjeĐtiǀe ǀalue ;OVͿ teŶds toǁards a target OV during the course of the 45 
optimisation [4,9]. Through implementing these methods of dynamic objective adjustment it has been shown that a single set of 46 
initial objectives can yield plans with minimised organ at risk (OAR) doses and consistently balanced trade-offs across all patients 47 
within a given treatment site [4,9,18]. In this manuscript, we define objectives whose weight and position are modified in this 48 
speĐifiĐ ŵaŶŶer as ͚dǇŶaŵiĐ oďjeĐtiǀes͛. 49 
A key challenge in all three approaches is adequately and intuitively capturing the oŶĐologist͛s eǆperieŶĐe aŶd decision making 50 
during the calibration process, such that automated plans are congruent with clinical preference. KBP is dependent on the 51 
optimality of large datasets of previous clinical plans, which is not guaranteed, and both ɸĐ and PB-AIO rely on trial and error to 52 
develop and refine automated protocols [19]. In this paper a novel solution to this problem is proposed through integrating Pareto 53 
navigation techniques directly into the calibration process.  54 
Pareto navigation enables operators to intuitively explore differing treatment plan options such that an informed choice can be 55 
made on the optimal balancing of competing trade-offs [20,21]. Navigation is performed on a pre-calculated set of Pareto optimal 56 
plans, which aim to sample clinically relevant parts of the Pareto surface. In this regard, a treatment plan is considered Pareto 57 
optimal when improvement of a given trade-off is only possible at the detriment of another, with the Pareto surface being 58 
represented by an infinite set of such plans. On an individual patient basis, intuitively exploring the Pareto surface through Pareto 59 
navigation has shown to reduce the need for trial and error, and yield plans more congruent with oŶĐologists͛ ĐliŶiĐal prefereŶĐes 60 
[22]. It is expected that incorporating Pareto navigation into the automated planning calibration process will yield similar benefits 61 
at the patient cohort level.  62 
The purpose of this work is to present the methodology of EdgeVcc (Experience Driven plan Generation Engine by Velindre Cancer 63 
Centre): a PB-AIO based automated planning solution, designed to be applicable across a range of radiotherapy treatment sites 64 
and uniquely calibrated using Pareto navigation principles. The first section of this paper provides a detailed description of the 65 
proposed methodology alongside its associated algorithms. The second section presents an example of its application to the 66 
tumour site of prostate and seminal vesicles (PSV).  67 
2. Methods and Materials 68 
2.1 Patient Dataset 69 
20 patients previously treated at Velindre Cancer Centre between July and December 2015 were randomly selected into a 70 
calibration (n=10) and validation (n=10) cohort. Patients were planned on computed tomography scans of 3 mm slice thickness 71 
with prostate, seminal vesicles, rectum, bladder and bowel delineated. Prostate + seminal vesicles were expanded 10 mm 72 
isotropically to form the planning target volume PTV48 and prostate expanded by 5mm (6 mm craniocaudally) to form PTV60, 73 
ǁith the PTV͛s suffiǆ deŶotiŶg its prescribed dose in Gy. All study patients were previously treated with VMAT on Elekta Agility 74 
linear accelerators with treatment plans generated manually in Oncentra Masterplan (v4.3, Elekta Ltd, Crawley) using a single 75 
6MV 360˚ arĐ, simultaneous integrated boost technique. Treatments were prescribed for 20 fractions, and manually planned to 76 
local clinical goals (supplementary table 1) using a class solution based methodology.   77 
2.2 Automated System 78 
2.2.1 System Overview  79 
The proposed solution (Fig.1) was developed in the treatment planning system RayStation (Raysearch Laboratories, Stockholm) 80 
using custom python scripts. For each tumour site a set of planning goals is defined within an ͚AutoPlaŶ protoĐol͛ (section 2.2.2). 81 
On a selected calibration patient(s) Pareto navigation techniques are utilised to derive a set of planning goal weighting factors, 82 
which correspond to a clinically desirable point on the Pareto surface for the given patient (section 2.2.4). The weighting factors 83 
are stored within the AutoPlan protocol, which then forms the input for automated planning of new patients. Automated plan 84 
generation is based on a PB-AIO fraŵeǁork ;seĐtioŶ Ϯ.Ϯ.ϯͿ that utilises ͚dǇŶaŵiĐ oďjeĐtiǀes͛ to eŶsure OAR doses are minimised 85 
and trade-off balancing for new patients is consistent with that selected during protocol calibration.   86 
2.2.2 AutoPlan Protocol  87 
The treatment modality, beam arrangement, standard PTV and planning volume at risk (PRV) margins, and planning goals are 88 
defined within the AutoPlan protocol. Planning goals guide the optimisation process and are stratified into three priority levels: 89 
primary normal tissue goals (P1), target goals (P2) and trade-off goals (P3). The optimisation methodology aims to meet goals in 90 
order of their priority, with compromise to target goals permissible by P1 but not P3. Trade-off goals are assigned a group number, 91 
which determines the order in which they are explored during the calibration process. Goals of the same parameter type and 92 
clinical relevance (e.g. low dose rectum objectives) are grouped to reduce degrees of freedom during calibration. The planning 93 
goals for PSV are presented in the supplementary table 2. 94 
Planning goals are designed to be clinically intuitive, with no specification of weighting factors required. Weighting factors are 95 
instead derived through two distinct processes. For P1 and P2, the clinical preference across all tumour sites when balancing 96 
conflicting goals is explicitly defined: target coverage is compromised to maintain normal tissue goals. Conflicting goals are 97 
therefore explicitly handled through region of interest (ROI) retraction algorithms, enabling weights to be defined by simple hard 98 
coded algorithms. In contrast, conflicting P3 trade-offs require careful balancing for each tumour site; a complex process requiring 99 
specialist clinical judgment. Weights are therefore derived through utilisation of Pareto navigation techniques (Section 2.2.4).  100 
2.2.3 PB-AIO Framework  101 
The following PB-AIO framework is used to generate both the final automated plans and those utilised during the calibration 102 
process.  103 
Auxiliary Optimisation Volumes  104 
Following PTV and PRV creation, a standard set of auxiliary optimisation ROIs (AuxROIs) are generated according to the algorithms 105 
detailed in the supplementary file S1. AuxROIs have two purposes. For conformity related planning goals AuxROIs enable a higher 106 
level of geometric specificity. For target goals, in line with ICRU 83 [23], AuxROIs subdivide each PTV into three sub-volumes to 107 
avoid conflicting planning aims:  PTVsv-1 is retracted from the skin surface and proximal primary OARs, PTVSV-2 consists of areas of 108 
PTV within the skin surface or extending into air, and PTVSV-3 is the PTV volume not covered by PTVSV-1 or PTVSV-2, which represents 109 
parts of PTV proximal to primary OARs. It is through this subdivision that P2 goals are compromised for P1 goals and IMRT flash is 110 
secured for superficial PTVs. 111 
Initial Optimisation Objectives  112 
Following treatment beam/arc definition an initial set of optimisation objectives are loaded into RayStation͛s Ŷatiǀe optimiser. 113 
Optimisation objectives are derived from the defined planning goals according to the algorithms specified in supplementary file 114 
S2, with the initial weight, winitial, for the ith objective defined by:  115 ݓ�௡����௟� = ݓ௡௢௠� ��� ��� �஼� �ே�   Eq. (1) 116 
where, ݓ௡௢௠� is the nominal weight of the planning goal from which the objective is derived, and ��� , ��� , �஼�  and �ே�  are optimisation 117 
objective specific scaling factors. Each scaling factor is summarised in table 1, with full definitions provided in the supplementary 118 
file S3. For P1 and P2 goals, ݓ௡௢௠�  is an empirically derived hardcoded value (supplementary table 3), intended to be common 119 
across all treatment sites. For P3 goals, ݓ௡௢௠�  is generated through the Pareto navigation calibration process.   120 
Plan Optimisation  121 
The employed optimisation algorithms (Fig. 2) consist of two stages: a pre-optimisation, which sets initial P3 objective target values 122 
(�௣ଷ� ) and a main optimisation, which generates the final clinical plan. During the optimisation process, P3 goals are implemented 123 
as ͚dǇŶaŵiĐ oďjeĐtiǀes͛ with the aim of minimising OAR doses and keeping trade-off balancing across patients consistent. In the 124 
following description of the methodology, we define ∆�  by the equation: 125 ∆�  = ஽�3� −��3�௫�                   Eq. (2) 126 
 127 
Where �௣ଷ�  is the current value of the planning goal͛s corresponding dose parameter (c.f. supplementary table 2) and ݔ�  equals 128 
DPresc for dose objectives and ��ை��  for volume objectives, where ��ை��  is the volume of the ith objective͛s ĐorrespoŶdiŶg ROI. 129 
For stage one, a fluence-based optimisation, which allows beam intensity to be modulated with minimal physical limits, is 130 
performed. Following the optimisation, if ∆�  does not lie within the range [0.15-0.5] (or [0.0-0.5] if �௣ଷ� =0) for each dynamic 131 
objective,  �௣ଷ�  is updated according to equation 3 (with the ǀariaďle ɷ set to 0.35) and the optimisation rerun. 132 �௣ଷ� = �௣ଷ� − ݔ��                  Eq. (3) 133 
The process is repeated until ∆�  lies within the specified bounds across all dynamic objectives. Bounding ∆�  in this manner ensures 134 
P3 optimisation objectives are a significant but not dominant component of the composite objective function, resulting in P3 goals 135 
being minimised without significantly compromising P1 or P2 goals. The resulting dose distribution, which is generated within 1-2 136 
minutes, provides an approximate prediction of the final, fully optimised, clinical solution. Based on this distribution,  �௣ଷ�  for the 137 
main optimisation is set according to Eq. 3 with ɷ=0.05. Fluence-based VMAT optimisations are not possible in RayStation, 138 
therefore stage one treatment arcs are approximated through 15 equi-spaced static IMRT fields. 139 
For stage two, a preliminary direct machine parameter optimisation (DMPO), ǁhere optiŵisatioŶs are ďouŶd ďǇ the ŵaĐhiŶe͛s 140 
physical limits, is executed to generate an initial set of segments. An optional modulation optimisation is performed where P2 141 
objective weights (ݓ௣ଶ� ) are reduced by a factor of 25 and, using the stage one pre-optimisation distribution as the reference dose, 142  �௣ଷ�  set according to Eq.3 ǁith ɷ=0.ϯ5. This prioritises the minimisation of P3 objectives during the initial phases of the plan 143 
generation process and results in a reduction of OAR doses at the lower dose levels in the final clinical plan. This however is at the 144 
expense of increased modulation and MU. After the modulation optimisation, objective positions and weights are reverted to 145 
their original values. Finally, in the main stage of the plan generation process, multiple DMPOs are performed with �௣ଷ�  and ݓ௣ଷ�   146 
adjusted after each round. Using the stage two dose distribution as the reference, �௣ଷ�  is updated according to Eq. 3 (with ɷ=0.05) 147 
and ݓ௣ଷ�  according to:  148 ݓ௣ଷ� = ை���௪��ை���                           Eq. (4) 149 
 150 
where, ݓ�� , ����  and ����  are the current weight, current OV and target OV of the ith objective respectively, with ����  derived from 151 ݓ௡௢�௠�  according to the supplementary file S4. A fuŶĐtioŶ͛s OV is defiŶed as the produĐt of its ǁeight aŶd fuŶĐtioŶ, therefore this 152 
iterative weight adjustment ensures that across the multiple DMPOs, ����  tends towards ����.  153 
2.2.4 AutoPlan Protocol Calibration 154 
A flowchart of the calibration process, used to generate ݓ௡௢௠�  for each P3 planning goal, is provided in the supplementary file S5. 155 
A calibration patient data set, consisting of typically 10-20 delineated patients, is defined. Froŵ this dataset a siŶgle ͚navigation 156 
patieŶt͛ is seleĐted aŶd the Pareto ŶaǀigatioŶ proĐess started. 157 
Initially all P3 nominal weights are set to zero. For the first P3 group, multiple plans (nominally five) are generated, each with a 158 
different value of ݓ௡௢௠�  applied to the group. The operator uses a slider to navigate through convex combinations of the differently 159 
weighted plans, with the navigated dose distribution and associated DVH updated in real time to inform the decision-making (Fig. 160 
3). The operator selects what they consider to be the optimum group weighting and the navigated weight is stored in the AutoPlan 161 
protocol. The process is then repeated for the next group using the updated protocol. Once all groups are navigated a final 162 
͚reďalaŶĐiŶg͛ ŶaǀigatioŶ is perforŵed oŶ a set of plans with differing factors (range 0.25 to 1.25) applied globally to all P3 nominal 163 
weights. This process allows the ratio of P3 weights, and P1 and P2 weights to be explored, ensuring a solution can be selected 164 
where higher priority goals are not compromised.  Once this first calibration round is complete the solution is tested across all 165 
calibration patients, with amendments to planning goals or additional navigations (on selected P3 groups) performed as required 166 
to refine the solution.  167 
Generating one set of navigation plans for a P3 group takes 1-3 hours, depending on plan complexity, and each group must be 168 
optimised and navigated sequentially. Navigations are initially performed on a single patient, however where there are large inter-169 
patient anatomical variations, repeat navigations over population outliers may be required to ensure the solution is robust across 170 
the whole patient cohort. When navigating over multiple patients the operator decides whether the P3 group weighting is based 171 
a particular patient, or averaged over multiple patients. The calibration process can be considered equivalent to navigating the 172 
Pareto surface one dimension (or P3 group) at a time, with operators using clinical experience and expertise to balance competing 173 
trade-offs. 174 
2.3 Application to Prostate Cancer  175 
All 10 calibration patients alongside their previous clinically approved treatment plan (VMATClinical) were available during the 176 
AutoPlan protocol calibration for PSV. Once successfully calibrated a final automated plan (VMATAuto) was generated for all study 177 
patients using identical arc configurations to VMATClinical. To assess the efficacy of the calibrated automated solution, plan quality 178 
was quantitatively compared to VMATClinical using the local clinical goals, alongside D98%, D2% and PaddiĐk͛s Conformity Index 179 
[24] for each target volume. The statistical significance of any differences was assessed using two-sided Wilcoxon matched-paired 180 
signed-rank tests.  181 
3. Results 182 
3.1. AutoPlan Protocol Calibration 183 
Protocol calibration was performed by one physicist with a radiation oncologist providing clinical input on trade-off prioritisation 184 
prior to calibration. 15 individual trade-off navigations were required to calibrate the AutoPlan protocol. All navigations were 185 
performed on a single patient, with planning goals manually modified twice after reviewing results across all patients in the 186 
calibration dataset. Key planning goal updates included the addition of bowel and low dose bladder planning goals. The final 187 
nominal weights are presented in supplementary table 3. 188 
3.2. Comparison with VMATClinical 189 
A summary of the quantitative comparison of VMATAuto and VMATClinical for the validation cohort is presented in Table 2. In 190 
comparison with the previous clinical plans, VMATAuto yielded statistically significant (p<0.05) improvements in: PTV conformity 191 
indices, high dose bladder metrics, mean bowel dose, and the majority of rectum dose metrics. Of particular note was the 192 
reduction in mean rectum dose (median 25.1 Gy vs. 27.5 Gy), rectum V24.3Gy (median 41.1% vs 46.4%), and improvements in CIPTV60 193 
(median 0.86 vs. 0.79) and CIPTV48 (median 0.84 vs. 0.77). Dosimetric improvements were not at the expense of other dose metrics, 194 
with observed detriments either statistically or clinically insignificant. In terms of modulation, VMATAuto yielded plans with a 195 
median MU 10% higher than VMATClinical.  196 
Extending the comparison across all 20 study patients yielded similar results (supplementary tables 4 and 5), with all treatment 197 
plans meeting the locally defined mandatory goals for clinical acceptability.  198 
4. Discussion 199 
To the authors͛ kŶoǁledge this paper presents the first automated planning solution that directly incorporates Pareto navigation 200 
techniques into the calibration process. Compared to clinical practice (table 2), VMATAuto consistently yielded plans with improved 201 
conformity and reduced organ at risk doses, with no clinically relevant compromise to other dose metrics. As VMATClinical and 202 
VMATAuto are generated in differing planning systems (Oncentra vs RayStation), these results are not intended to form a robust 203 
assessment as to their relative efficacy, this is the subject of future work. Instead they provide sound evidence that directly 204 
calibrating automated solutions through Pareto navigation is feasible and yield plans of improved dosimetric quality compared to 205 
current clinical practice.    206 
Utilisation of Pareto navigation within the calibration process was observed to have two main benefits. Firstly, exploring differently 207 
weighted options via a sliding interface and live dose distribution allowed trade-off options to be explored in a visually intuitive 208 
manner. Secondly, an automated solution was derived in a time efficient manner with minimal trial and error. These advantages 209 
have been demonstrated on a per-patient basis by a number of studies [22,25,26] and this work indicates that similar benefits can 210 
be realised by applying this technique at a patient cohort level.  211 
A potential weakness of Pareto navigation is that there can be clinically relevant discrepancies between the navigated dose 212 
distribution and that of the final deliverable plan [27]. To minimise these discrepancies the following approaches were adopted. 213 
Firstly, the Pareto surface was sampled one dimension at a time to reduce interpolation errors during navigation (whilst 214 
maintaining a reasonable computational cost). Secondly, the Pareto dataset was populated with deliverable plans, ensuring 215 
navigations were performed on clinically achievable solutions. By utilising these approaches, discrepancies throughout the 216 
calibration process were of negligible clinical significance (supplementary table 6). This navigation methodology does however 217 
have a potential weakness, in that by limiting the navigation to one P3 group at a time a full exploration of the Pareto surface is 218 
not performed. Whilst this was not considered a problem for the relatively simple site of PSV cancer, for more complex sites, 219 
navigation of multiple P3 groups in parallel may be required to derive the most clinically desirable solution. 220 
An interesting finding from this study was that Pareto navigation across a single patient appears sufficient for a successful 221 
calibration. Whilst modifications to planning goals were required after reviewing results across all calibration patients, these 222 
adjustments were due to deficiencies in the original set of planning goals, which were highlighted by differing patient geometries 223 
(e.g. proximity of bowel to PTV demonstrating requirement for bowel planning goals), rather than an inappropriate calibration. 224 
The ability to calibrate automated solutions against small patient cohorts (5-10 subjects) is in-line with examples in the literature 225 
for ɸĐ [8] and PB-AIO [10] solutions, and should enable a more efficient automation of novel techniques or protocols than KBP 226 
solutions, which require the manual generation of large patient datasets for each change in clinical practice.  227 
The implemented calibration methodology requires algorithms that balance trade-offs consistently across differing patients. 228 
Dynamically adapting trade-off objective positions and weights during the optimisation was hypothesised to fulfil this function. 229 
By implementing ͚dǇŶaŵiĐ oďjeĐtiǀes͛ a single calibrated AutoPlan protocol was found to yield appropriately balanced, clinically 230 
acceptable plans across all 20 study patients. In terms of robustness to patient geometry, even when PTV/OAR overlap differed 231 
considerable from the navigation patient, trade-off balancing was observed to be appropriate (Fig. 4).  232 
In summary, a novel automated planning solution has been developed, which for the first time directly incorporates Pareto 233 
navigation into the calibration process. The solution has been successfully calibrated for the site of PSV, yielding clinically 234 
acceptable, appropriately balanced treatment plans, fully autonomously.   235 
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Table 1   
Summary of objective weight scaling factors 
Scaling Factor Description FVi  Scales objective weight according the volume of its corresponding ROI. FTi  Scales objective weight according to the objective's target dose level (DTi ). This 
removes an unwanted dependency of RayStation's objective functions on DTi . FCi  A hardcoded constant utilised to reduce the weight of PTV sub-volume objectives to 
avoid skin boosting and reduce conflicts within the PTV/OAR overlap region.  FNi  FNi  enables winitiali  to be modified for an individual planning goal. The purpose is to 
bring winitiali  closer to the anticipated final weight for dynamic objectives. 
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Table 2 
Dosimetric comparison of VMATAuto and VMATClinical for the validation patient cohort  
    VMATAuto   VMATClinical     
  Metric Median Range   Median Range   p value 
PTV60 D98% (Gy) 57.8 57.7 to 58.0   57.9 57.6 to 58.3   0.17 
  D2% (Gy) 61.7 61.6 to 61.7   61.7 61.3 to 62.2   0.33 
  CI 0.86 0.85 to 0.87   0.79 0.76 to 0.82   0.01 
PTV48  D98% (Gy) 46.8 46.5 to 47.4   47.0 46.6 to 47.7   0.06 
  D2% (Gy) 58.8 58.5 to 59.2   59.4 58.8 to 59.8   0.01 
  CI 0.84 0.82 to 0.87   0.77 0.75 to 0.79   0.01 
Rectum V24.3Gy (%) 41.1 27.3 to 63.6   46.4 30.6 to 66.1   0.01 
  V40.5Gy (%) 24.2 15.3 to 39.6   24.6 16.4 to 41.2   0.06 
  V52.7Gy (%) 11.0 4.7 to 16.5   12.8 5.6 to 18.9   0.01 
  V60.8Gy (%) 0.1 0.0 to 0.5   0.0 0.0 to 0.3   0.09 
  DMean (Gy) 25.1 17.5 to 32.3   27.5 20.5 to 34.0   0.01 
Bladder V40.5Gy (%) 15.3 8.8 to 31.5   15.4 8.9 to 31.0   0.39 
  V52.7Gy (%) 7.8 3.0 to 16.8   8.0 3.3 to 17.9   0.04 
  V56.8Gy (%) 5.3 2.1 to 11.7   5.7 2.3 to 12.8   0.03 
  DMean (Gy) 18.7 13.1 to 30.7   19.1 13.9 to 31.2   0.51 
Bowel V36.5Gy (cm³) 0.0 0.0 to 0.7   0.0 0.0 to 0.9   0.27 
  V44.6Gy (cm³) 0.0 0.0 to 0.0   0.0 0.0 to 0.1   0.32 
  DMean (Gy) 6.4 3.4 to 11.2   7.5 3.9 to 14.1   0.01 
External D1.8cm³  (Gy) 61.6 61.5 to 61.8   61.7 61.2 to 62.4   0.33 
Plan MU MU 600 582 to 653   546 496 to 627   0.01 
Statistical significance: results where p<=0.05 are presented in bold 
CI: Paddick's Conformity Index for the specified PTV.     
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Figure Legends 311 
Fig. 1. Flowchart depicting the workflow of the proposed solution, with all items within the PB-AIO framework (as represented by 312 
the dashed area) fully automated. For each tumour site a calibrated AutoPlan protocol is required.   313 
Fig. 2. Flowchart of the stage 1 and stage 2 optimisation algorithms, where:  ݓ௣ଶ� , �௣ଷ� , ݓ௣ଷ� , ∆�  and ɷ are defined in the main 314 
manuscript, DynObj is an abbreviation for dynamic objectives and DMPO indicates a direct machine parameter optimisation. 315 
*During the modulation optimisation, for Eq. 3, �௣ଷ�  is calculated from the final stage one pre-optimisation distribution. 316 
Fig. 3. (LHS) Screenshots demonstrating using the slider GUI to navigate through different weighted options for the PSV 317 
conformality goal (P3 group 4).  The displayed DVH metrics, which are not part of the calibration GUI, demonstrate the trade-off 318 
ďetǁeeŶ the PaddiĐk͛s ĐoŶforŵitǇ iŶdeǆ ;CIͿ for ďoth PTVs aŶd orgaŶ at risk ŵeaŶ doses. Isodose legeŶd is eŶlarged for Đlarity. 319 
(RHS) Algorithms associated with the navigation module where: wj and wj+1 are the nominal weights of the nearest neighbour 320 
plans j and j+1 respectively, whose weights bound the navigation weight, wnav; Dj and Dj+1 correspond to the dose distribution of 321 
plan j and j+1 respectively; and Dnav represents the estimated navigated dose distribution. 322 
Fig. 4. DVH and dose distributions for the navigation patient (LHS) and patient 7 in the validation cohort (RHS), demonstrating the 323 
robustness of the automated solution to different anatomy. For both patients the DVH results for VMATClinical are provided for 324 
reference (dashed line). For patient 7 the overlap of rectum with PTV60 and PTV48 was 9% and 24% respectively (c.f. 4% and 13% 325 
respectively for the navigation patient), and for bladder 8% and 19% respectively (c.f. 1% and 4% for the navigation patient). The 326 
PTV/OAR overlaps for patient 7 were all greater than the 89th percentile when considering the overlaps of all 20 study patients. 327 
